Verastem, Inc. (LON:0LOV)

Market Cap	259.50M -16.4%
Revenue (ttm)	37.55M +395.9%
Net Income	-146.89M
EPS	-1.83
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,814
Open	3.900
Previous Close	3.940
Day's Range	3.900 - 4.180
52-Week Range	3.600 - 11.168
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Verastem

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine ki...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 102
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LOV

Financial Performance

In 2025, Verastem's revenue was $30.91 million, an increase of 209.14% compared to the previous year's $10.00 million. Losses were -$209.47 million, 60.3% more than in 2024.

Financial numbers in USD